Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: BARI increases GvHD-suppressive Tregs by preserving JAK3 signaling.
Fig. 2: Inhibition of EGFR signaling by erlotinib diminishes GvHD recovery mediated by BARI.


  1. 1.

    Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7:340–52.

    CAS  Article  Google Scholar 

  2. 2.

    Choi J, Ziga ED, Ritchey J, Collins L, Prior JL, Cooper ML, et al. IFNgammaR signaling mediates alloreactive T-cell trafficking and GVHD. Blood. 2012;120:4093–103.

    CAS  Article  Google Scholar 

  3. 3.

    Choi J, Cooper ML, Alahmari B, Ritchey J, Collins L, Holt M, et al. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect. PLoS One. 2014;9:e109799.

    Article  Google Scholar 

  4. 4.

    Ashami K, DiPersio JF, Choi J. Targeting IFNGR/IL6R or downstream JAK1/JAK2 to control GvHD. Oncotarget. 2018;9:35721–2.

    Article  Google Scholar 

  5. 5.

    Choi J, Cooper ML, Staser K, Ashami K, Vij KR, Wang B, et al. Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia. 2018;32:2483–94.

    CAS  Article  Google Scholar 

  6. 6.

    Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000;19:2566–76.

    CAS  Article  Google Scholar 

  7. 7.

    Moriggl R, Topham DJ, Teglund S, Sexl V, McKay C, Wang D, et al. Stat5 is required for IL-2-induced cell cycle progression of peripheral T cells. Immunity. 1999;10:249–59.

    CAS  Article  Google Scholar 

  8. 8.

    Ferrara JL, Smith CM, Sheets J, Reddy P, Serody JS. Altered homeostatic regulation of innate and adaptive immunity in lower gastrointestinal tract GVHD pathogenesis. J Clin Invest. 2017;127:2441–51.

    Article  Google Scholar 

  9. 9.

    Castilla-Llorente C, Martin PJ, McDonald GB, Storer BE, Appelbaum FR, Deeg HJ, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014;49:966–71.

    CAS  Article  Google Scholar 

  10. 10.

    Alahmari B, Cooper ML, Vij K, Ritchey J, Ruminski P, Gao F, et al. Selective targeting of α4β1 integrin attenuates murine graft versus host disease. Leukemia. 2020;34:3100–4.

    Article  Google Scholar 

  11. 11.

    Fu YY, Egorova A, Sobieski C, Kuttiyara J, Calafiore M, Takashima S, et al. T cell recruitment to the intestinal stem cell compartment drives immune-mediated intestinal damage after allogeneic transplantation. Immunity. 2019;51:90–103. e3

    CAS  Article  Google Scholar 

  12. 12.

    Barberan S, Fraguas S, Cebria F. The EGFR signaling pathway controls gut progenitor differentiation during planarian regeneration and homeostasis. Development. 2016;143:2089–102.

    CAS  PubMed  Google Scholar 

  13. 13.

    Aihara E, Engevik KA, Montrose MH. Trefoil factor peptides and gastrointestinal function. Annu Rev Physiol. 2017;79:357–80.

    CAS  Article  Google Scholar 

  14. 14.

    Martin JL, de Silva HC, Lin MZ, Scott CD, Baxter RC. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade. Mol Cancer Ther. 2014;13:316–28.

    CAS  Article  Google Scholar 

  15. 15.

    Liu B, Guo Z, Dong H, Daofeng T, Cai Q, Ji B, et al. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2. Brain Res. 2015;1611:93–100.

    CAS  Article  Google Scholar 

Download references


JC is supported by Amy Strelzer Manasevit Research Program (the Be The Match Foundation and the National Marrow Donor Program), Alvin J. Siteman Cancer Center Siteman Investment Program (supported by the Foundation for Barnes-Jewish Hospital Cancer Frontier Fund, National Cancer Institute Cancer Center Support Grant, P30 CA091842, and Barnard Trust), Bigelow Aerospace (OTM 13489), Washington University SPORE-CDP in Leukemia (P50 CA171963), Washington University DDRCC grant (P30 DK052574), and the Bryan Thomas Campbell Foundation. JFD is supported by Bigelow Aerospace (OTM 13489), Washington University NCI/NIH SPORE in Leukemia (P50 CA171963), NCI Outstanding Investigator Award (R35 CA210084), and the Bryan Thomas Campbell Foundation. KA is supported by Washington University SPORE Diversity Program (P50 CA171963). MAC is supported by R01DK109384 and The Lawrence C. Pakula MD IBD Research Fund at Washington University.

Author information




Conceptualization: JFD and JC; methodology: SK, KA, JFD and JC; investigation and validation: SK, KA, SL, KS, KV, SS, JR, SP, FG, MAC, JC; formal analysis: SK, KA, SL, KS, KV, SS, JC; writing for the first version of the manuscript: SK, KA, JC; visualization: SK, KA, SL, KS, JC; supervision: JC; funding acquisition: JFD and JC.

Corresponding author

Correspondence to Jaebok Choi.

Ethics declarations

Competing interests

JC received honorarium from Incyte Corporation, received research funding from Mallinckrodt Pharmaceuticals, and served as a consultant for Daewoong Pharmaceutical. JFD served on advisory boards for Incyte Corporation, CellWorks, Macrogenics, Amphivena, Arch, Rivervest, and Bioline and is a co-Founder of Magenta Therapeutics and WUGen. MLC is a co-Founder and Chief Scientific Officer of WUgen. MAC previously had research grants from Incyte Corporation. The other authors declare no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kim, S., Ashami, K., Lim, S. et al. Baricitinib prevents GvHD by increasing Tregs via JAK3 and treats established GvHD by promoting intestinal tissue repair via EGFR. Leukemia (2021).

Download citation


Quick links